Pulsed Electromagnetic Fields (PEMFS) in Complex Regional Pain Syndrome Type i (CRPS-I) of the Foot (PeCFoA) ((PeCFoA))

PEMFS in Patients With CRPS-I of the Foot and Ankle: a Randomized Controlled Trial

The investigators hypothesize that the association of I-ONE® therapy with standard rehabilitation treatment can optimize the clinical and functional recovery of patients with pulsed electromagnetic fields (PEMFs) (I-ONE® therapy) of the foot or ankle.

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

Study design; spontaneous, prospective, randomized study with control group.

Purpose of the study:

evaluate the functional clinical improvement of the foot/ankle joint with algodystrophic pathology following a standard rehabilitation treatment and home biophysical treatment and local biophysical stimulation with I-ONE® therapy (IGEA SpA).

Study Type

Interventional

Enrollment (Estimated)

28

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Diagnosis of type I CRPS according to the Budapest criteria (table 1)
  • Type I CRPS involving the ankle or foot
  • Onset of CRPS type I up to a maximum of 3 years after the symptomatic event
  • Pain on visual analog scale (VAS) scale quantified as intensity at least ≥ 5 at recruitment
  • Pharmacological treatment with first infusion cycle of neridronate

Exclusion Criteria:

  • Neurological pathologies (stroke, degenerative, traumatic pathologies)
  • Local neurological impairment (type II CRPS), confirmed by a conduction test or similar
  • Cardiac pacemaker, treatment site malignancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: I-ONE group
The group will undergo home biophysical treatment with I-ONE® therapy (experimental group) for 4 hours/day for 60 days. Patients will follow standard rehabilitation treatment: patients will perform active and active-assisted range of motion (ROM) recovery exercises and stretching exercises for 30 minutes per day, for 6 weeks.

I-ONE® is a medical device certified by the Ministry of Health as a Medical Device (risk class II A) for the treatment of inflammatory and degenerative tissue pathologies. The device consists of a signal generator and an applicator, called a solenoid. The solenoid will be placed on the joint, not necessarily in direct contact with the skin. The device works with a rechargeable battery and is equipped with an hour counter to assess patient compliance.

Treatment with I-ONE® therapy will start within 3-7 days of recruitment, will last 6 hours a day and will be maintained for 60 days. The treatment will be carried out at home and the device will be delivered directly to the patient's home by courier.

Other Names:
  • I-One, IGEA, Italy
No Intervention: Exercise group
The group, not subjected to biophysical therapy, will be controls. Patients will follow standard rehabilitation treatment: patients will perform active and active-assisted ROM recovery exercises and stretching exercises for 30 minutes per day, for 6 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain at movement
Time Frame: Change from baseline at 3 months
Pain evoked by passive movement (ankle and toe joints for foot involvement) was rated as 0=none, 1=mild, 2=moderate, 3=severe, by direct comparison with the healthy contralateral limb)
Change from baseline at 3 months
Pain at movement
Time Frame: Change from baseline at 6 months
Pain evoked by passive movement (ankle and toe joints for foot involvement) was rated as 0=none, 1=mild, 2=moderate, 3=severe, by direct comparison with the healthy contralateral limb)
Change from baseline at 6 months
Pain at movement
Time Frame: Change from baseline at 12 months
Pain evoked by passive movement (ankle and toe joints for foot involvement) was rated as 0=none, 1=mild, 2=moderate, 3=severe, by direct comparison with the healthy contralateral limb)
Change from baseline at 12 months
Pain intensity
Time Frame: Change from baseline at 3 months
Visual Analogue Scale (VAS): the Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').
Change from baseline at 3 months
Pain intensity
Time Frame: Change from baseline at 6 months
Visual Analogue Scale (VAS): the Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').
Change from baseline at 6 months
Pain intensity
Time Frame: Change from baseline at 12 months
Visual Analogue Scale (VAS): the Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').
Change from baseline at 12 months
Pain intensity
Time Frame: at 12 months
Visual Analogue Scale (VAS): the Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').
at 12 months
Rate of edema
Time Frame: Change from baseline at 3 months
• Local edema (score 0=none, 1=mild, 2=moderate, 3=severe, at the level of the ankle and midfoot, by direct comparison with the healthy contralateral limb)
Change from baseline at 3 months
Rate of edema
Time Frame: Change from baseline at 6 months
• Local edema (score 0=none, 1=mild, 2=moderate, 3=severe, at the level of the ankle and midfoot, by direct comparison with the healthy contralateral limb)
Change from baseline at 6 months
Rate of edema
Time Frame: Change from baseline at 12 months
• Local edema (score 0=none, 1=mild, 2=moderate, 3=severe, at the level of the ankle and midfoot, by direct comparison with the healthy contralateral limb)
Change from baseline at 12 months
Number of participants with allodynia
Time Frame: Change from baseline at 3 months
• Clinical assessment of allodynia (tested as pain by lightly stroking with a small brush (end of a cotton swab: dichotomic present/absent response)
Change from baseline at 3 months
Number of participants with allodynia
Time Frame: Change from baseline at 6 months
• Clinical assessment of allodynia (tested as pain by lightly stroking with a small brush (end of a cotton swab: dichotomic present/absent response)
Change from baseline at 6 months
Number of participants with allodynia
Time Frame: Change from baseline at 12 months
• Clinical assessment of allodynia (tested as pain by lightly stroking with a small brush (end of a cotton swab: dichotomic present/absent response)
Change from baseline at 12 months
Number of participants with hyperalgesia
Time Frame: Change from baseline at 3 months
Clinical evaluation of hyperalgesia (defined as a pin prick-evoked stimulus perceived as something more painful or longer than the duration of the stimulus in the affected limb compared to the contralateral limb: dichotomic present/absent response)
Change from baseline at 3 months
Number of participants with hyperalgesia
Time Frame: Change from baseline at 12 months
Clinical evaluation of hyperalgesia (defined as a pin prick-evoked stimulus perceived as something more painful or longer than the duration of the stimulus in the affected limb compared to the contralateral limb: dichotomic present/absent response)
Change from baseline at 12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluate a better recovery of joint functionality
Time Frame: Change from baseline at 3 months
•• American Foot & Ankle Score (AOFAS): scores range from 0 to 100, with healthy ankles receiving 100 points.
Change from baseline at 3 months
Evaluate a better recovery of joint functionality
Time Frame: Change from baseline at 6 months
•• American Foot & Ankle Score (AOFAS): scores range from 0 to 100, with healthy ankles receiving 100 points.
Change from baseline at 6 months
Evaluate a better recovery of joint functionality
Time Frame: Change from baseline at 12 months
•• American Foot & Ankle Score (AOFAS): scores range from 0 to 100, with healthy ankles receiving 100 points.
Change from baseline at 12 months
Self-reporting measure of pain
Time Frame: Change from baseline at 3 months
McGill Pain Questionnaire: scores range from 0 (no pain) to 78 (severe pain)
Change from baseline at 3 months
Self-reporting measure of pain
Time Frame: Change from baseline at 6 months
McGill Pain Questionnaire: scores range from 0 (no pain) to 78 (severe pain)
Change from baseline at 6 months
Self-reporting measure of pain
Time Frame: Change from baseline at 12 months
McGill Pain Questionnaire: scores range from 0 (no pain) to 78 (severe pain)
Change from baseline at 12 months
patient assessment of pain and limitations of activity
Time Frame: Change from baseline at 3 months
he Roles and Maudsley score is a subjective 4-point patient assessment of pain and limitations of activity (1 = excellent result with no symptoms following treatment; 2 = significant improvement from pre-treatment; 3 = patient somewhat improved; 4 = poor, symptoms identical or worse than pre- treatment)
Change from baseline at 3 months
patient assessment of pain and limitations of activity
Time Frame: Change from baseline at 6 months
he Roles and Maudsley score is a subjective 4-point patient assessment of pain and limitations of activity (1 = excellent result with no symptoms following treatment; 2 = significant improvement from pre-treatment; 3 = patient somewhat improved; 4 = poor, symptoms identical or worse than pre- treatment)
Change from baseline at 6 months
patient assessment of pain and limitations of activity
Time Frame: Change from baseline at 12 months
he Roles and Maudsley score is a subjective 4-point patient assessment of pain and limitations of activity (1 = excellent result with no symptoms following treatment; 2 = significant improvement from pre-treatment; 3 = patient somewhat improved; 4 = poor, symptoms identical or worse than pre- treatment)
Change from baseline at 12 months
Number of participants taking medications
Time Frame: Change from baseline at 3 months
• Assessment report for Non-Steroidal Anti-Inflammatory Drugs
Change from baseline at 3 months
Number of participants taking medications
Time Frame: Change from baseline at 6 months
• Assessment report for Non-Steroidal Anti-Inflammatory Drugs
Change from baseline at 6 months
Number of participants taking medications
Time Frame: Change from baseline at 12 months
• Assessment report for Non-Steroidal Anti-Inflammatory Drugs
Change from baseline at 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2023

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

June 1, 2027

Study Registration Dates

First Submitted

June 8, 2023

First Submitted That Met QC Criteria

June 19, 2023

First Posted (Actual)

June 28, 2023

Study Record Updates

Last Update Posted (Actual)

September 22, 2023

Last Update Submitted That Met QC Criteria

September 21, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Foot Diseases

Clinical Trials on I-One

3
Subscribe